Penumbra (NYSE:PEN) Upgraded by Wall Street Zen to “Buy” Rating

Penumbra (NYSE:PEN) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other equities analysts also recently commented on the company. Wells Fargo & Company assumed coverage on Penumbra in a report on Tuesday, November 18th. They set an “underweight” rating for the company. Robert W. Baird set a $345.00 price objective on shares of Penumbra in a report on Tuesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a research note on Monday. Citigroup upgraded Penumbra from a “neutral” rating to a “buy” rating and raised their target price for the company from $285.00 to $350.00 in a research note on Thursday, December 11th. Finally, JPMorgan Chase & Co. upgraded Penumbra from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $275.00 to $370.00 in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $333.47.

Penumbra Trading Up 0.2%

Shares of PEN stock opened at $315.98 on Friday. The business has a 50-day moving average of $274.47 and a 200 day moving average of $260.85. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18. Penumbra has a 1-year low of $221.26 and a 1-year high of $320.00. The stock has a market capitalization of $12.37 billion, a PE ratio of 75.59, a P/E/G ratio of 2.60 and a beta of 0.66.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.07. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The firm had revenue of $354.69 million during the quarter, compared to analyst estimates of $340.77 million. During the same quarter in the prior year, the firm posted $0.85 earnings per share. The business’s quarterly revenue was up 17.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Penumbra will post 3.67 earnings per share for the current year.

Insider Activity

In other Penumbra news, EVP Johanna Roberts sold 300 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $300.13, for a total transaction of $90,039.00. Following the completion of the sale, the executive vice president directly owned 63,836 shares in the company, valued at $19,159,098.68. The trade was a 0.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Harpreet Grewal sold 100 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $292.98, for a total transaction of $29,298.00. Following the sale, the director directly owned 8,416 shares of the company’s stock, valued at approximately $2,465,719.68. This represents a 1.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 34,744 shares of company stock valued at $10,387,474 in the last 90 days. 4.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Machina Capital S.A.S. purchased a new stake in shares of Penumbra during the second quarter worth about $369,000. First Trust Advisors LP boosted its position in shares of Penumbra by 4.0% during the second quarter. First Trust Advisors LP now owns 100,723 shares of the company’s stock worth $25,849,000 after acquiring an additional 3,906 shares during the last quarter. Fortis Capital Advisors LLC bought a new stake in Penumbra in the 1st quarter valued at $732,000. Belpointe Asset Management LLC purchased a new stake in Penumbra in the 1st quarter worth $732,000. Finally, Janney Montgomery Scott LLC boosted its holdings in shares of Penumbra by 716.5% during the 2nd quarter. Janney Montgomery Scott LLC now owns 24,749 shares of the company’s stock valued at $6,351,000 after purchasing an additional 21,718 shares during the last quarter. 88.88% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Penumbra

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: JPMorgan upgraded PEN from Neutral to Overweight and bumped its target to $370 (from $275), signaling stronger conviction in Penumbra’s growth trajectory and implying meaningful upside vs. the current share level. JP Morgan Upgrades Penumbra (PEN)
• Positive Sentiment: Truist raised its price target to $370 from $312 and reiterated a Buy, reinforcing the bullish view and matching JPMorgan’s $370 target that implies roughly mid‑teens upside from current levels. Penumbra upgraded to overweight from neutral at JPMorgan
• Positive Sentiment: Additional price-target lifts from RBC (to $355 from $325) and Canaccord (to $359 from $355) add to the consensus upward drift in sell‑side expectations. These moves tighten the buy-side narrative around recurring CAVT adoption and international growth. Penumbra price target raised to $359 from $355 at Canaccord Penumbra price target raised to $355 from $325 at RBC Capital
• Positive Sentiment: Needham reiterated a Buy rating, supporting the positive analyst tone and reducing near‑term downside risk from the sell‑side. Needham maintains Penumbra (PEN) buy recommendation
• Positive Sentiment: Clinical/outcomes coverage: a published evaluation of Penumbra’s CAVT in intermediate‑risk pulmonary embolism (PE) patients highlights outcomes and resource‑utilization benefits—supportive evidence for broader clinical adoption and reimbursement discussions. Penumbra’s CAVT Evaluated for Outcomes and Resource Utilization in Intermediate-Risk PE Patients
• Neutral Sentiment: Media/awareness: Bloomberg’s healthcare segment highlighted Penumbra’s efforts to expand CAVT awareness—positive for long‑term market penetration but more of a brand/voice play than an immediate revenue driver. Vanguards of Health Care: Penumbra Expands CAVT Awareness

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.